National Institutes of Health

Description

The Chronic Kidney Disease Biomarkers Consortium [CKD BioCon] was established in September 2009 as a result of RFA-DK-08-015 [Chronic Kidney Disease Biomarker Discovery and Validation Consortium (U01)] to develop, validate and qualify biomarkers based on existing biosamples from well-characterized CKD patients with longitudinal follow-up. The second phase of the CKD BioCon was funded in September 2014, pursuant to RFA DK-14-011. Two additional Centers were brought into the Consortium in 2015. The CKD BioCon currently consists of eight Participating Clinical Centers (PCCs) and is actively engaged in multiple research protocols. The DCC's goalover the next two years will enhance biomarker research in CKD by a) providing ongoing logistical support, expertise and statistical support to consortial work involving one or more PCCs, b) supervising the proposal, approval and progress of consortial studies, and supporting the conduct of the studies, and c) supervising transfer of data and samples between members of the consortium and repository activities of the consortium, as well as the NIDDK repository.

Who can apply

• Public and State controlled institutions of higher education

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV